Radhika Kolla, MD
Internal Medicine · Davenport, IANPI 1598744096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 25.5% of the total. Reporting peaked in 2022 at $1,178 and has fallen 83.3% since, to $196 in 2025. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$885
- Novo Nordisk$361
- Astellas Pharma US Inc$259
- Amgen$255
- Lilly USA, LLC$199
- Dexcom, Inc.$180
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,23593%
- Education$2307%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $885 |
| Novo Nordisk | 24 | $361 |
| Astellas Pharma US Inc | 5 | $259 |
| Amgen | 18 | $255 |
| Lilly USA, LLC | 12 | $199 |
| Dexcom, Inc. | 10 | $180 |
| Pfizer | 9 | $170 |
| AstraZeneca | 9 | $151 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 4 | $112 |
| Johnson & Johnson | 5 | $77 |
| Boehringer Ingelheim | 3 | $75 |
| Exact Sciences | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $69 |
| GSK | 4 | $65 |
| Novartis | 3 | $64 |
| Harmony Biosciences LLC | 2 | $46 |
| Eisai Inc. | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Lupin Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,465 in reported general payments places this provider in the 90th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 122 | $128,493 |
| MounjaroTirzepatide | 74 | $103,675 |
| OzempicSemaglutide | 78 | $79,469 |
| ProliaDenosumab | 34 | $58,596 |
| EliquisApixaban | 64 | $56,481 |
| FarxigaDapagliflozin Propanediol | 47 | $50,737 |
| MyrbetriqMirabegron | 43 | $35,263 |
| InvokanaCanagliflozin | 22 | $26,166 |
| JanuviaSitagliptin Phosphate | 18 | $16,244 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $15,433 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $14,625 |
| XareltoRivaroxaban | 19 | $13,505 |
| LinzessLinaclotide | 11 | $6,913 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $5,938 |
| Raloxifene Hcl | 107 | $4,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $75 | $128,493122 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $199 | $105,049111 claims |
| Novo NordiskOzempic | $361 | $79,46978 claims |
| AmgenProlia | $255 | $58,59634 claims |
| PfizerEliquis | $170 | $56,48164 claims |
| AstraZenecaFarxiga, Symbicort | $151 | $53,14658 claims |
| Johnson & JohnsonInvokana, Xarelto | $77 | $39,67141 claims |
| Astellas Pharma US IncMyrbetriq | $259 | $35,26343 claims |
| GSKTrelegy Ellipta | $65 | $14,62516 claims |
| AbbVieLinzess, Synthroid | $885 | $9,41751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Davenport
- Alex SiegDavenport$4K
- James HahnDavenport$1K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.